Healthcare Industry News: BiO2 Medical
News Release - November 18, 2013
BiO2 Medical Executes Q4 2013 Commercialization Strategy for the Angel(R) Catheter, Signing Distribution Partnership Agreements in Key European and Middle Eastern GeographiesSAN ANTONIO, Texas, Nov. 18, 2013 -- (Healthcare Sales & Marketing Network) -- BiO2 Medical has achieved Q4 2013 global expansion goals for the Angel® Catheter, a novel Central Venous Catheter (CVC) with a permanently attached retrievable Inferior Vena Cava (IVC) filter to provide Pulmonary Embolism (PE) protection for critically ill patients. The Angel® Catheter is the first IVC filter to receive a prophylactic use indication and was designed for bedside placement in the ICU.
In addition to the UK, the company has signed with strategic distribution partners in Turkey, Sweden, Denmark, Norway, and the Netherlands, increasing the availability of the Angel® Catheter throughout Europe and the Middle East.
The Nordic countries are well known for their commitment to improving quality of care, providing an open environment to introduce innovative technologies like the Angel® Catheter to reduce the incidence of hospital acquired PE.
Along with its geographic link to the Middle East and Western Europe, the Turkish market is attractive for US medical device companies due to recent government backed investments in healthcare, making Turkey a destination for medical tourism in the region.
BiO2 Medical assessed the potential in these regions and subsequently partnered with FG Grup (Turkey), MedCore (Sweden, Denmark, Norway), and TD Medical (Netherlands) to distribute the Angel® Catheter.
According to Yunus Cakiroglu, General Coordinator of FG Grup, "Recent healthcare investments have created more private hospitals, prompting the need for innovative products to improve the standard of care. The Angel® Catheter fits this description perfectly and complements our portfolio."
"Consistent support from the medical community combined with increasingly positive clinical outcomes show promising indications of the global viability of this product line. Commercial expansion into key geographies such as these strengthens our global presence," stated Patrick Howe, VP of Sales & Marketing for BiO2 Medical.
BiO2 Medical has ongoing negotiations with future distribution partners, to facilitate further expansion of the Angel® Catheter in Europe and the Middle East for Q1 2014.
BiO2 Medical, Inc., is a U.S.A. based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado. BiO2 Medical has created BiO2 Medical Ltd., a UK subsidiary to facilitate commercialization efforts.
For more information on BiO2 Medical and the Angel® Catheter, please visit www.bio2medical.com. For more information on FG Grup, MedCore, and TD Medical, please visit www.fggrup.com.tr, www.en.medcore.se, and www.tdmedical.nl.
Source: BiO2 Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.